Literature DB >> 15884093

Using patient characteristics and attitudinal data to identify depression treatment preference groups: a latent-class model.

Jennifer A Thacher1, Edward Morey, W Edward Craighead.   

Abstract

A latent-class model is used to identify and characterize groups of patients who share similar attitudes towards treating depression. The results predict the probability of preference-group membership on the basis of observable characteristics and answers to attitudinal questions. Understanding the types of preference groups that exist and a patient's probability of membership in each of the groups can help clinicians tailor the treatment to the patient and may increase patient adherence. One hundred four depressed patients completed a survey on attitudes towards treatment of Major Depressive Disorder. Analysis shows that treatment preferences vary among depressed patients. Three classes are identified that differ in their sensitivity to treatment costs and side effects. One class cares primarily about treatment effectiveness; side effects and the cost of treatment have little impact on this class's treatment decisions. Another class is highly sensitive to cost and side effects. A third class is somewhat sensitive to cost and side effects. Younger and male patients are more likely to be sensitive to treatment costs and side effects. (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15884093     DOI: 10.1002/da.20057

Source DB:  PubMed          Journal:  Depress Anxiety        ISSN: 1091-4269            Impact factor:   6.505


  5 in total

1.  Economic factors in of patients' nonadherence to antidepressant treatment.

Authors:  Haekyung Jeon-Slaughter
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2012-03-14       Impact factor: 4.328

2.  Depressed patients' perceptions of depression treatment decision-making.

Authors:  Daniela Simon; Andreas Loh; Celia E Wills; Martin Härter
Journal:  Health Expect       Date:  2007-03       Impact factor: 3.377

3.  Cancer genetic risk assessment and referral patterns in primary care.

Authors:  Hetal S Vig; Joanne Armstrong; Brian L Egleston; Carla Mazar; Michele Toscano; Angela R Bradbury; Mary B Daly; Neal J Meropol
Journal:  Genet Test Mol Biomarkers       Date:  2009-12

4.  Cancer patients' trade-offs among efficacy, toxicity, and out-of-pocket cost in the curative and noncurative setting.

Authors:  Yu-Ning Wong; Brian L Egleston; Kush Sachdeva; Naa Eghan; Melanie Pirollo; Tammy K Stump; John Robert Beck; Katrina Armstrong; Jerome Sanford Schwartz; Neal J Meropol
Journal:  Med Care       Date:  2013-09       Impact factor: 2.983

5.  Assessment of preferences for treatment: validation of a measure.

Authors:  Souraya Sidani; Dana R Epstein; Richard R Bootzin; Patricia Moritz; Joyal Miranda
Journal:  Res Nurs Health       Date:  2009-08       Impact factor: 2.228

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.